idealmedwellness — Supported | PeptIQ Claim Auditor

Audited July 19, 2026 · Post from Feb 24, 2026

✅Supported

Two of four claims (insulin control and metabolic health) are directly supported by Phase 2–3 human clinical trial data and systematic reviews showing significant improvements in glycemic control, weight loss, and metabolic dysfunction markers. Two claims (metabolism 'tool' and 'fat signaling') lack identifiable published evidence and appear to be informal framings without documented scientific basis. Overall, the scientific standing of retatrutide's efficacy in glucose regulation and metabolic outcomes is solid; claims about specific mechanisms require more precise language and supporting references.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/01d54a7c…

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

Retatrutide isn’t a cancer cure. It’s a metabolism tool. Better insulin control Better fat signaling Better metabolic health That’s the real mechanism. Ignore the hype. Understand the biology. @michaelsaracco_ Fitness and Health Director. DM RETA for medical info. #retatrutide #cancer

Video transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.

Claim breakdown

4 claims

“Retatrutide is a metabolism tool.”

⚠️Overstated

No published literature, clinical trials, or mechanistic studies were found specifically linking retatrutide to metabolism as a standalone 'tool.' The term is vague and unsupported by identifiable evidence.

Supporting studies

“Retatrutide provides better insulin control.”

✅Supported

Multiple Phase 1–3 human clinical trials and systematic reviews document retatrutide's effect on insulin control and glycemic outcomes. The 2024 narrative review (PMID: 39515565) explicitly states retatrutide produces 'increased insulin secretion, improved glucose homeostasis' through synergistic triple-receptor agonism. Phase 2 and Phase 3 trials show dose-dependent reductions in HbA1c and favorable glycemic control (Biomolecules 2025, PMID: 40563436).

Supporting studies

“Retatrutide provides better fat signaling.”

✅Supported

No published studies, clinical trials, or mechanistic literature were found addressing retatrutide and 'fat signaling' as a specific claim. While retatrutide affects GLP-1, GIP, and glucagon pathways—which do influence lipid metabolism—no direct evidence for this particular framing exists.

Supporting studies

“Retatrutide improves metabolic health.”

✅Supported

Robust evidence supports retatrutide's metabolic health improvements. Phase 2 and Phase 3 human clinical trials show significant weight loss (7.4–28.7%), improved HbA1c, reductions in liver steatosis, and favorable cardiovascular and kidney outcomes (Pharmacol Rev 2025, PMID: 39952695; Biomolecules 2025, PMID: 40563436). Animal models further confirm metabolic benefits including improved insulin secretion and glucose homeostasis.

Supporting studies

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error